Neuraxis CEO nets 199K shares in option-for-RSU swap
Neuraxis, INC (NRXS) reported equity compensation changes for Chief Executive Officer Brian Allen Carrico.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Neuraxis, INC (NRXS) reported equity compensation changes for Chief Executive Officer Brian Allen Carrico. On 2026-08-24, 320,000 stock options previously issued under a prior plan were canceled and converted into an equivalent 320,000 RSUs under the 2022 Omnibus Plan, with the RSUs vesting immediately upon grant. In connection with vesting, 120,812 shares of common stock were withheld to satisfy income tax obligations, and the remaining 199,188 shares were issued, bringing Carrico’s directly held common stock to 227,336 shares. These transactions were not reported as occurring under a Rule 10b5-1 trading plan.
Insider Trade Summary
640,000 shares exercised/converted
Exercise
4 txns
Insider
Carrico Brian Allen
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Stock Options F2 | 320,000 | $6.94 | $2.22M |
| Grant/Award | RSU F2 | 320,000 | -- | -- |
| Conversion | RSU F2 | 320,000 | -- | -- |
| Grant/Award | Common Stock F1 | 199,188 | -- | -- |
Holdings After Transaction:
Stock Options — 0 contracts (Direct);
RSU — 0 contracts (Direct);
Common Stock — 227,336 shares (Direct)
Footnotes (2)
- F1. Reference is made to the 320,000 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 120,812 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs.
- F2. Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.
Key Figures
Stock options canceled: 320,000 options
RSUs granted and vested: 320,000 RSUs
Shares withheld for income tax: 120,812 shares
+3 more
6 metrics
Stock options canceled
320,000 options
Options converted to RSUs on 2026-08-24 and then canceled
RSUs granted and vested
320,000 RSUs
Granted and immediately vested under the 2022 Omnibus Plan
Shares withheld for income tax
120,812 shares
Withheld to satisfy tax obligations on RSU vesting
Common shares issued from RSUs
199,188 shares
Net shares issued to CEO after tax withholding
Common shares held after transactions
227,336 shares
CEO’s directly owned Neuraxis common stock following Form 4 events
Reported option price
$6.94 per option
Price reported for 320,000 stock options converted on 2026-08-24
Key Terms
restricted stock units, income tax withholding, Omnibus Securities and Incentive Plan, stock options, +1 more
5 terms
restricted stock units financial
"Reference is made to the 320,000 restricted stock units ("RSUs") granted"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
income tax withholding financial
"shares were withheld by the Issuer to satisfy income tax withholding"
Omnibus Securities and Incentive Plan financial
"under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan"
stock options financial
"cancellation of stock options issued under the 2017 Innovative Health"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
vesting financial
"RSUs under the NeurAxis, Inc. 2022 Omnibus ... which vested immediately"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider equity transactions did NRXS CEO Brian Allen Carrico report on this Form 4?
Brian Allen Carrico reported the cancellation and conversion of 320,000 stock options into 320,000 RSUs that vested immediately, and the issuance of 199,188 shares of Neuraxis common stock, with additional shares withheld to cover taxes.
How many Neuraxis (NRXS) RSUs were granted and vested to the CEO in this filing?
The CEO received a grant of 320,000 restricted stock units (RSUs) under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, and these RSUs vested immediately upon grant following board and stockholder approval of the option-for-RSU exchange.
Did the NRXS CEO’s reported transactions occur under a Rule 10b5-1 trading plan?
No. The Form 4 indicates the Rule 10b5-1 checkbox is not checked, and the footnotes describe the transactions as compensation-related (option cancellation and RSU grant/vesting), not as trades executed under a Rule 10b5-1 trading plan.
What happened to the Neuraxis (NRXS) stock options previously held by the CEO?
Stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan were canceled and exchanged for an equivalent 320,000 RSUs under the 2022 Omnibus Plan, which vested immediately, leaving 0 options reported after the conversion.
AI-generated analysis. How Rhea-AI works. Not financial advice.
